Clinical meaning
Short-acting beta-2 agonists (SABAs) and inhaled corticosteroids (ICS) serve fundamentally different roles in asthma management. SABAs (albuterol/salbutamol) activate beta-2 adrenergic receptors on bronchial smooth muscle, increasing intracellular cAMP via adenylyl cyclase, causing rapid bronchodilation within 5-15 minutes lasting 4-6 hours. SABAs provide symptomatic relief but do NOT address the underlying airway inflammation that drives asthma pathophysiology. ICS (fluticasone, budesonide, beclomethasone) suppress airway inflammation by binding intracellular glucocorticoid receptors, translocating to the nucleus, and modulating gene transcription: they reduce eosinophil recruitment, decrease cytokine production (IL-4, IL-5, IL-13), inhibit mast cell mediator release, reduce mucus hypersecretion, and reverse airway remodeling over time. GINA 2023 guidelines no longer recommend SABA-only treatment for any step of asthma management. Even in Step 1 (mild intermittent asthma), as-needed low-dose ICS-formoterol is preferred over SABA alone because patients with 'mild' asthma still have airway inflammation and are at risk for severe exacerbations. Over-reliance on SABA (using ≥3 canisters/year) is a marker of poorly controlled asthma and is associated with increased risk of exacerbations and death. The NP must shift from the old paradigm (SABA as first-line) to the current evidence-based approach (ICS-containing therapy from the start).